BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 9643506)

  • 1. The molecular genetics of central nervous system tumors.
    Ng HK; Lam PY
    Pathology; 1998 May; 30(2):196-202. PubMed ID: 9643506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined molecular genetic studies of chromosome 22q and the neurofibromatosis type 2 gene in central nervous system tumors.
    Ng HK; Lau KM; Tse JY; Lo KW; Wong JH; Poon WS; Huang DP
    Neurosurgery; 1995 Oct; 37(4):764-73. PubMed ID: 8559307
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathways leading to glioblastoma multiforme: a molecular analysis of genetic alterations in 65 astrocytic tumors.
    Lang FF; Miller DC; Koslow M; Newcomb EW
    J Neurosurg; 1994 Sep; 81(3):427-36. PubMed ID: 8057151
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular pathogenesis of pediatric astrocytic tumors.
    Nakamura M; Shimada K; Ishida E; Higuchi T; Nakase H; Sakaki T; Konishi N
    Neuro Oncol; 2007 Apr; 9(2):113-23. PubMed ID: 17327574
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
    Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
    Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q.
    Boström J; Cobbers JM; Wolter M; Tabatabai G; Weber RG; Lichter P; Collins VP; Reifenberger G
    Cancer Res; 1998 Jan; 58(1):29-33. PubMed ID: 9426052
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of malignant gliomas.
    Rasheed BK; Wiltshire RN; Bigner SH; Bigner DD
    Curr Opin Oncol; 1999 May; 11(3):162-7. PubMed ID: 10328589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of heterozygosity on chromosome 19 in secondary glioblastomas.
    Nakamura M; Yang F; Fujisawa H; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 2000 Jun; 59(6):539-43. PubMed ID: 10850866
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Roles of the functional loss of p53 and other genes in astrocytoma tumorigenesis and progression.
    Nozaki M; Tada M; Kobayashi H; Zhang CL; Sawamura Y; Abe H; Ishii N; Van Meir EG
    Neuro Oncol; 1999 Apr; 1(2):124-37. PubMed ID: 11550308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
    Ohgaki H; Kleihues P
    J Neuropathol Exp Neurol; 2005 Jun; 64(6):479-89. PubMed ID: 15977639
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas.
    Tohma Y; Gratas C; Biernat W; Peraud A; Fukuda M; Yonekawa Y; Kleihues P; Ohgaki H
    J Neuropathol Exp Neurol; 1998 Jul; 57(7):684-9. PubMed ID: 9690672
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of histology and molecular genetic analysis of 1p, 19q, 10q, TP53, EGFR, CDK4, and CDKN2A in 91 astrocytic and oligodendroglial tumors.
    Ueki K; Nishikawa R; Nakazato Y; Hirose T; Hirato J; Funada N; Fujimaki T; Hojo S; Kubo O; Ide T; Usui M; Ochiai C; Ito S; Takahashi H; Mukasa A; Asai A; Kirino T
    Clin Cancer Res; 2002 Jan; 8(1):196-201. PubMed ID: 11801559
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene.
    Barbashina V; Salazar P; Holland EC; Rosenblum MK; Ladanyi M
    Clin Cancer Res; 2005 Feb; 11(3):1119-28. PubMed ID: 15709179
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular genetic alterations in glioblastomas with oligodendroglial component.
    Kraus JA; Lamszus K; Glesmann N; Beck M; Wolter M; Sabel M; Krex D; Klockgether T; Reifenberger G; Schlegel U
    Acta Neuropathol; 2001 Apr; 101(4):311-20. PubMed ID: 11355302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
    Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
    Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular genetic analysis of non-astrocytic gliomas.
    Tong CY; Ng HK; Pang JC; Hui AB; Ko HC; Lee JC
    Histopathology; 1999 Apr; 34(4):331-41. PubMed ID: 10231401
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular genetic aspects of oligodendrogliomas including analysis by comparative genomic hybridization.
    Bigner SH; Matthews MR; Rasheed BK; Wiltshire RN; Friedman HS; Friedman AH; Stenzel TT; Dawes DM; McLendon RE; Bigner DD
    Am J Pathol; 1999 Aug; 155(2):375-86. PubMed ID: 10433931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Genes implicated in glial tumors].
    Sanson M; Marie Y; Huguet S; He J; Hoang-Xuan K
    Morphologie; 2000 Jun; 84(265):51-5. PubMed ID: 11048299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preferential inactivation of the p53 tumor suppressor pathway and lack of EGFR amplification distinguish de novo high grade pediatric astrocytomas from de novo adult astrocytomas.
    Sung T; Miller DC; Hayes RL; Alonso M; Yee H; Newcomb EW
    Brain Pathol; 2000 Apr; 10(2):249-59. PubMed ID: 10764044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular genetic evidence for subtypes of oligoastrocytomas.
    Maintz D; Fiedler K; Koopmann J; Rollbrocker B; Nechev S; Lenartz D; Stangl AP; Louis DN; Schramm J; Wiestler OD; von Deimling A
    J Neuropathol Exp Neurol; 1997 Oct; 56(10):1098-104. PubMed ID: 9329453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.